

APPENDIX

CLAIMS BEING APPEALED

- 1 A composition comprising human monoclonal antibodies that bind specifically to human tumor necrosis factor alpha.
- 2 The composition of claim 1 wherein the antibodies comprise antibodies of the IgM type.
- 3 The composition of claim 1 wherein the antibodies comprise antibodies of the IgG type.
- 4 The composition of claim 1 in a pharmaceutically acceptable carrier.
- 5 The composition of claim 1 wherein the antibodies are suitable for intravenous administration.
- 6 The composition of claim 1 wherein the antibodies also bind to mouse tumor necrosis factor alpha.

- 7 The composition of claim 1 wherein the antibodies are specific for tumor necrosis factor alpha.
- 8 The composition of claim 1 wherein the antibodies can bind to non-neutralizing epitopes of tumor necrosis factor alpha.
- 9 The composition of claim 1 wherein the antibodies bind to tumor necrosis factor alpha on human cell surfaces.
- 10 The composition of claim 1 wherein the antibodies inhibit secretion of tumor necrosis factor alpha.
- 11 The composition of claim 1 wherein the antibody is expressed from the cell line designated F78-1A10-B5 (ATCC Deposit CRL 11306).
- 12 A human monoclonal antibody preparation characterized by binding specifically to human TNF alpha, and having a titer comparable to three high affinity neutralizing mouse monoclonal antibodies when tested by ELISA.

- 13 The antibody of claim 11 having the further characteristic of binding to cell surface
TNF alpha on cells selected from the group consisting of human T cells, B cells,
monocytes and lymphoid or monocyte lineage cell lines of human origin.

- 14 The antibody of claim 11 having the further characteristic of inhibiting LPS induced
TNF alpha secretion by human monocyte-like cells.